Hyperbaric oxygen therapy is an adjunct to neurosurgical drainage and broad-spectrum intravenous antibiotics for intracranial abscess, including brain-parenchymal abscess, subdural empyema, and epidural empyema. It is most useful when multiple abscesses are present, when the abscess is in a surgically inaccessible location, when the patient is a poor surgical candidate, or when the infection has not responded adequately to surgery and antibiotics alone. Intracranial abscess is recognised by Health Canada as one of the 14 conditions for which provincial health insurance covers HBOT at hospital-based programmes.
Quick Answer
Does HBOT help intracranial abscess? Hyperbaric oxygen therapy is an adjunct to neurosurgical drainage and broad-spectrum intravenous antibiotics for intracranial abscess, including brain-parenchymal abscess, subdural empyema, and epidural empyema. It is most useful when multiple abscesses are present, when the abscess is in a surgically inaccessible location, when the patient is a poor surgical candidate, or when the infection has not responded adequately to surgery and antibiotics alone. Intracranial abscess is recognised by Health Canada as one of the 14 conditions for which provincial health insurance covers HBOT at hospital-based programmes.
Intracranial abscess is a focal collection of pus inside the cranial vault. The category includes brain-parenchymal abscess (a discrete pus-filled cavity within the brain tissue itself), subdural empyema (pus between the dura mater and arachnoid), and epidural empyema (pus between the skull and the dura mater). Each carries significant morbidity and mortality despite modern neurosurgery, broad-spectrum antibiotics, and intensive-care support, with mortality typically 10 to 20 percent and neurological sequelae in 30 to 50 percent of survivors.
The most common pathways to intracranial abscess are direct extension from contiguous infection (sinusitis, otitis media, mastoiditis, dental infection), hematogenous seeding from a remote source (endocarditis, pulmonary infection, intra-abdominal source), and direct inoculation (penetrating trauma, neurosurgical procedure, congenital dermoid sinus). Risk factors include uncontrolled diabetes mellitus, immunosuppression (transplant recipients, HIV/AIDS, chronic steroid use), congenital heart disease with right-to-left shunt, and intravenous drug use. Microbiology is typically polymicrobial and depends on source: streptococci, staphylococci, Bacteroides, and other anaerobes for direct-extension cases; nocardia and toxoplasma in immunosuppressed patients.
Classic presentation is the "triad" of headache, focal neurological deficit, and fever, although fewer than half of patients have all three. Headache is the most consistent feature; fever is present in only 50 to 60 percent of cases. Other features include altered mentation, seizure, papilloedema (raised intracranial pressure), and signs related to the location of the abscess. Diagnosis is made by contrast-enhanced CT or MRI showing a ring-enhancing lesion with surrounding oedema, often supported by aspiration culture from a stereotactic biopsy or surgical drainage. Time from presentation to surgical drainage and antibiotics is the strongest single determinant of outcome.
Hyperbaric oxygen therapy acts on intracranial abscess through four convergent mechanisms.
First, restoration of neutrophil bactericidal activity. The oxygen-dependent oxidative burst that neutrophils use to kill bacteria requires tissue pO2 above 30 mmHg. Brain abscess cavities and the surrounding edematous brain are profoundly hypoxic. HBOT at 2.0 to 2.5 ATA raises tissue pO2 to several hundred mmHg during each session, restoring full neutrophil killing capacity at the abscess margin and in the surrounding brain.
Second, anaerobic suppression. Many brain-abscess organisms (Bacteroides, Fusobacterium, Prevotella, anaerobic streptococci) are obligate or facultative anaerobes that grow poorly or stop replicating at the elevated tissue oxygen tensions HBOT delivers.
Third, antibiotic synergy. HBOT enhances the activity of certain antibiotics with known oxygen-dependent intracellular accumulation or oxidative-burst potentiation, including fluoroquinolones and certain beta-lactams. This is particularly relevant in the abscess cavity and the hypoxic peri-abscess parenchyma where standard antibiotic delivery is impaired.
Fourth, oedema reduction and ICP support. HBOT causes hyperoxic vasoconstriction in well-oxygenated brain while preserving or improving oxygenation in the hypoxic peri-abscess zone. This combination reduces cerebral oedema, improves intracranial pressure dynamics, and supports the survival of marginally viable brain tissue around the abscess. The effect is most pronounced in cases with significant mass effect from peri-abscess oedema.
Typical Treatment Protocol
The standard adjunctive protocol is 2.0 to 2.5 ATA on 100 percent oxygen for 90 minutes per session. The first sessions are typically delivered within 24 to 48 hours of surgical drainage, with once-daily treatment continuing for the duration of antibiotic therapy. Some programmes use a more intensive twice-daily regimen for the first 5 to 7 days for severe or multi-locular cases. Total course is typically 10 to 20 sessions, occasionally extended for residual infection or persistent oedema on imaging. HBOT is delivered between surgical procedures and during the long IV antibiotic course, NEVER as a substitute for or as a delay to surgical drainage when drainage is feasible. The decision to add HBOT is made jointly by the neurosurgical team, infectious diseases, and the hyperbaric medicine team, typically once the patient is stable enough for chamber transport (post-operative day 1 or 2 in most cases).
Level B - Moderate Evidence
Supported by controlled studies and clinical evidence
Multiple case-series reviews and the older hyperbaric literature describe substantially reduced mortality with adjunctive HBOT in intracranial abscess compared to historical surgery-and-antibiotics baselines. Reported HBOT-treated mortality is in the single digits versus the 10 to 20 percent baseline often cited from the pre-HBOT era, with the strongest signal in multi-focal abscess and in patients who had failed initial surgery and antibiotics.
The Bartek et al. cohort study (Acta Neurochir 2016, 40 adult patients with spontaneous brain abscess) reported significantly fewer reoperations in the HBOT-adjuvant group (10 percent versus 45 percent in standard care, p=0.03) and better long-term Glasgow Outcome Scores (GOS 5 in 80 percent versus 45 percent, p=0.04). Randomised trials are not feasible for ethical reasons in this life-threatening condition.
HBOT restores neutrophil oxygen-dependent killing capacity at tissue oxygen tensions only reachable at 2.0 ATA and above. Normobaric oxygen alone does not achieve this in the hypoxic abscess cavity or peri-abscess brain.
Anaerobic and microaerophilic organisms (Bacteroides, Fusobacterium, Prevotella, anaerobic streptococci) common in brain abscess are inhibited at the elevated tissue oxygen tensions HBOT delivers, supporting bacteriologic control.
The standard adjunctive protocol is 2.0 to 2.5 ATA, 90 minutes per session, once daily (twice daily for the first 5 to 7 days in severe or multi-locular cases), for a total course of 10 to 20 sessions paralleled with the IV antibiotic course.
In Ontario, urgent inter-facility transfer for adjunctive HBOT is coordinated through CritiCall Ontario (1-800-668-4357), which provides 24/7 physician-to-physician triage between the neurosurgical team and the receiving hyperbaric programme.
Highest-evidence-tier studies tagged to this condition in the Canada Hyperbarics research database, ranked by evidence tier (1 = meta-analysis or RCT, 2 = cohort, 3 = case series), most recent first.
Undersea Hyperb Med · 2021 · Review
Current opinion in infectious diseases · 2017 · Meta-Analysis
Acta Neurochir (Wien) · 2016 · Cohort Study
J Clin Neurol · 2014 · Study
Undersea Hyperb Med · 2012 · Review
Patients with intracranial abscess are typically managed in a neurosurgical critical-care setting. The first procedure is stereotactic aspiration or open surgical drainage, which provides both source-control and microbiology for targeted antibiotic therapy. Broad-spectrum IV antibiotics start before surgery and continue through the post-operative period for typically four to eight weeks total. The treating team adds adjunctive HBOT when the patient is stable enough for chamber transport, usually within 24 to 48 hours of surgery.
In Ontario, inter-facility transfer for adjunctive HBOT is coordinated through CritiCall Ontario at 1-800-668-4357. In other provinces the call goes directly to the hospital chamber. HBOT is most often delivered in multiplace chambers (large enough to accommodate a stretcher, ventilator, infusion pumps, and a hyperbaric-trained nurse and physician inside the chamber alongside other patients) because of the critical-care needs of the typical patient. Some centres use monoplace chambers with purpose-designed pass-throughs.
Pressurisation takes five to ten minutes, the treatment phase at 2.0 to 2.5 ATA on 100 percent oxygen lasts 90 minutes, and decompression takes another five to ten minutes. Sessions are typically once daily for 10 to 20 total sessions, paralleled with antibiotic therapy and serial neuroimaging. The neurosurgery team, infectious diseases, neurology, and hyperbaric medicine all participate in management. Cognitive and motor recovery from intracranial abscess can be prolonged; rehabilitation needs are addressed during and after the acute hyperbaric course.
Intracranial abscess is recognised by Health Canada as one of the 14 conditions for which hyperbaric oxygen is the established standard of adjunctive care. Treatment is delivered at the 11 hospital-based hyperbaric programmes across seven provinces under provincial health insurance.
In Ontario, OHIP covers treatment at the three hospital programmes (Toronto General / UHN, Hamilton General Hospital, The Ottawa Hospital). CritiCall Ontario at 1-800-668-4357 is the standard line for inter-facility transfer coordination, particularly given that most intracranial-abscess cases originate in community hospitals without an in-house chamber. In British Columbia, treatment is at Vancouver General Hospital's Leon Judah Blackmore Pavilion, with BC Ambulance critical-care transport for cases originating outside the Lower Mainland. In Alberta, both Misericordia Edmonton (Covenant Health) and the Foothills Medical Centre / AJECCC Calgary (Alberta Health Services) accept intracranial-abscess referrals, with the Alberta hospital billing code 13.99I (per 15 minutes). RAMQ covers treatment at Hôpital du Sacré-Cœur de Montréal and Hôtel-Dieu de Lévis in Quebec. MSI (Nova Scotia), MCP (Newfoundland and Labrador), and Saskatchewan also cover their respective hospital programmes.
For patients in provinces or territories without an in-province hospital programme (Manitoba, New Brunswick, Prince Edward Island, Yukon, Northwest Territories, Nunavut), urgent inter-provincial transfer is arranged through the receiving province's transfer service. Most such cases route to Misericordia Edmonton (for prairie and territorial patients) or the Ontario hospital programmes. Coordination with the local neurosurgical team is essential because the patient typically requires continued neurosurgical care during the HBOT course.
Hyperbaric oxygen therapy for the 14 Health Canada-recognised conditions, including Intracranial Abscess, is delivered at the 11 hospital hyperbaric programmes located in seven provinces (Ontario, Quebec, British Columbia, Alberta, Nova Scotia, Newfoundland and Labrador, and Saskatchewan). The six provinces and territories without an in-province hospital programme (Manitoba, New Brunswick, Prince Edward Island, Yukon, Northwest Territories, and Nunavut) route patients to the nearest receiving hospital programme. Use the links below for province-specific coverage, referral pathway, and emergency routing details.
Hospital + Private
OHIP (Ontario Health Insurance Plan)
Hospital Only
MSP (Medical Services Plan)
Hospital + Private
Alberta Health / AHCIP
Hospital Only
RAMQ
Disrupted
Saskatchewan Health Authority
No Hospital Chamber
Manitoba Health
Hospital Only
MSI (Medical Services Insurance)
No Hospital Chamber
Medicare NB
Hospital Only
MCP (Medical Care Plan)
Out-of-Province Referral
Health PEI
Out-of-Province Referral
Yukon Health and Social Services
Out-of-Province Referral
NWT Health and Social Services
Out-of-Province Referral
Nunavut Department of Health
For acute or emergency presentations of Intracranial Abscess, call 911 first. The receiving emergency department coordinates urgent transfer to the nearest hospital hyperbaric programme through the relevant provincial transfer network (CritiCall Ontario at 1-800-668-4357, BC Patient Transfer Network, EHS Nova Scotia, or equivalent). For diving-related emergencies, the Divers Alert Network (DAN) emergency hotline is 1-919-684-9111.
Untreated pneumothorax is the only absolute contraindication, because trapped intrathoracic air expands on decompression and can cause tension pneumothorax. Severely raised intracranial pressure with impending herniation is a relative contraindication and requires individual judgement; the brief hyperoxic vasoconstriction during HBOT can actually reduce ICP in many cases, but uncontrolled malignant ICP requires neurosurgical decompression first. Other relative contraindications include severe hemodynamic instability requiring continuous vasopressor titration (chamber-side titration is more difficult), uncontrolled seizure disorder (HBOT can lower the seizure threshold; concurrent anticonvulsant therapy is standard for intracranial-abscess patients in any case), severe chronic obstructive pulmonary disease with bullous lung disease, and concurrent treatment with bleomycin or disulfiram. None of these are typically allowed to override the hyperbaric decision in a patient with multi-focal abscess, deep-seated abscess, or surgically inaccessible disease, given the high mortality and morbidity of under-treated intracranial infection.
No. Surgical drainage (stereotactic aspiration or open drainage) remains the primary treatment when feasible, providing both source-control and microbiology for targeted antibiotic therapy. HBOT is added as an adjunct after surgery, or in cases where surgery is not feasible because of abscess location, multi-focality, or patient comorbidity.
HBOT is most beneficial when multiple abscesses are present, when the abscess is in a surgically inaccessible location, when the patient is a poor surgical candidate, when the infection has not responded adequately to surgery and antibiotics, or when there is significant peri-abscess oedema with mass effect. The decision is made jointly by neurosurgery, infectious diseases, and hyperbaric medicine.
Case series and systematic reviews suggest adjunctive HBOT is associated with reduced mortality and reduced need for repeat surgery compared to standard surgery and antibiotics alone. The evidence base is observational, not randomised, because randomised trials are not ethically feasible in this life-threatening condition.
As soon as the patient is stable for chamber transport after the initial surgical drainage, typically within 24 to 48 hours of surgery. Some programmes use twice-daily HBOT for the first 5 to 7 days in severe or multi-locular cases.
Typical course is 10 to 20 sessions at 2.0 to 2.5 ATA on 100 percent oxygen for 90 minutes per session, delivered once daily (twice daily for the first 5 to 7 days in severe cases). Total course is paralleled with the four to eight week IV antibiotic course.
Yes. Intracranial abscess is recognised by Health Canada and covered at all 11 hospital-based hyperbaric programmes under OHIP, MSP, AHCIP, RAMQ, MSI, MCP, and Saskatchewan Health. For patients in provinces without an in-province hospital programme, urgent inter-facility transfer is arranged through provincial transfer services such as CritiCall Ontario (1-800-668-4357).
Yes. The Health Canada-recognised indication includes brain-parenchymal abscess, subdural empyema, and epidural empyema. The same protocol (2.0 to 2.5 ATA, 90 minutes per session, 10 to 20 total sessions paralleled with surgical drainage and IV antibiotics) applies.
Yes. Surgically inaccessible abscesses are precisely the population in which HBOT has the strongest signal of benefit, because surgery cannot provide source-control. HBOT plus prolonged IV antibiotics is the standard non-surgical strategy in this scenario, and the evidence base from case series and reviews supports this approach.
For ventilated or critically ill patients, the chamber session feels like routine ICU care with the addition of pressurisation. Multiplace chambers accommodate stretchers, ventilators, infusion pumps, and a hyperbaric-trained nurse and physician inside the chamber. Pressurisation takes five to ten minutes and feels like an aircraft descent. The treatment phase at 2.0 to 2.5 ATA on 100 percent oxygen lasts 90 minutes. Decompression takes another five to ten minutes. The patient is continuously monitored throughout.
Yes, in many cases. The brief hyperoxic vasoconstriction during HBOT reduces blood-flow to well-oxygenated brain while preserving or improving flow to the hypoxic peri-abscess zone, often reducing peri-abscess oedema and intracranial pressure on serial imaging. In cases of severely elevated, malignant ICP with impending herniation, neurosurgical decompression must come first.
All 11 Canadian hospital hyperbaric programmes accept intracranial-abscess referrals from neurosurgery teams. The Canada Hyperbarics verified directory at canadahyperbarics.ca/facilities/ lists all programmes with phone numbers, addresses, and current operational status. In Ontario, urgent transfer is coordinated through CritiCall Ontario at 1-800-668-4357.